BiotechTube

turoctocog alfa

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Congenital Bleeding Disorder

Conditions

Congenital Bleeding Disorder, Haemophilia A

Trial Timeline

Mar 1, 2018 → Apr 22, 2019

NCT ID
NCT03449342

About turoctocog alfa

turoctocog alfa is a approved stage product being developed by Novo Nordisk for Congenital Bleeding Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03449342. Target conditions include Congenital Bleeding Disorder, Haemophilia A.

What happened to similar drugs?

3 of 20 similar drugs in Congenital Bleeding Disorder were approved

Approved (3) Terminated (0) Active (17)
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
🔄turoctocog alfa pegolNovo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄vatreptacog alfa (activated) + eptacog alfa (activated)Novo NordiskPhase 3
🔄nonacog beta pegolNovo NordiskPhase 3
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (12)

NCT IDPhaseStatus
NCT06574984Pre-clinicalRecruiting
NCT04584892Pre-clinicalCompleted
NCT03179748Pre-clinicalCompleted
NCT03588741Phase 3Terminated
NCT03449342ApprovedCompleted
NCT02941354Phase 1Completed
NCT02207218Pre-clinicalCompleted
NCT02035384Pre-clinicalCompleted
NCT01493778Phase 3Completed
NCT01365520Phase 1Completed
NCT01238367Phase 1Completed
NCT00840086Phase 3Completed

Competing Products

20 competing products in Congenital Bleeding Disorder

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
KW-3357Kyowa KirinPhase 1
29
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
27
Sandostatine LPNovartisPhase 2
35
mycophenolate mofetilRochePhase 1
29
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
29
Advate® + turoctocog alfaNovo NordiskPhase 1
29